UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity

UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity

UM-164 is a dual inhibitor of c-Src and p38 MAPK, and has been a lead compound for targeting triple-negative breast cancer. UM-164 shows stronger binding to the active sites of Src compared with the conventional Src inhibitor Dasatinib. While Dasatinib has displayed some inhibitory effects on glioma...

Full description

Bibliographic Details
Main Authors: Huizhe Xu, Ye Zhang, Jia Liu, Jing Cui, Yu Gan, Zhisheng Wu, Youwei Chang, Rui Sui, Yi Chen, Ji Shi, Haiyang Liang, Qiang Liu, Shulan Sun, Haozhe Piao
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
UM-164
glioma
YAP
proliferation
c-Src
p38
Online Access:https://www.mdpi.com/2072-6694/14/21/5343

Internet

https://www.mdpi.com/2072-6694/14/21/5343

Similar Items